+34 620 10 75 37info@nanbiosis.com

Nanbiosis

U3. Synthesis of Peptides Unit

U3. Synthesis of Peptides Unit

  • Scientific Director: Dr. Miriam Royo miriam.royo@iqac.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC
IQAC CSIC

Order request

This Unit is coordinated by the Multivalent Systems for Nanomedicine goup at IQAC-CSIC and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio an Dra. Miriam Royo in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the IQAC-CSIC.

Active projects

Title Fundin: Organism Call: Funding source Role
ICTS-2017-10-CIBER-2 Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperiment Ministerio de Economía, Industria y Competitividad (MINECO) Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) Coordinator
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U3

08 Nov

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed audience. On Tuesday 7 EHD and BBN sessions will specific for each area in separate rooms (with common coffee break). Posters of both areas were on display in the exhibit hall throughout the entirety of the Annual Meeting. Moreover, at the “Posters & beers” session (Monday[...]

20 Jan

New nanoarchitectonics of RGD peptide developed using quatsomes as robust tool in tissue engineering.

Researchers of three groups of CIBER-BBN at CSIC and IBEC, have created a versatile platform based on hierarchically nanostructured RGD peptide using quatsomes, with proved enhanced cell adhesion. These findings, which arose within the framework of the intramural project of CIBER-BBN “Molecular Biointerfaces for cell guidance” (DynaMo4Vasc), open new possibilities for tissue engineering. The participation of two NANBIOSIS units were acknowledged in the publication of the research results: the synthesis of RGD derivatives were performed at NANBIOSIS U3 “Synthesis of peptides unit” of CIBER-BBN at IQAC−CSIC.  And the design and characterization of quatsomes were done at U6 of NANBIOSIS “Biomateria[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

28 Feb

Fabry Desease in the Rare Disease Day: A New Hope

WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...]

03 Feb

Multivalent self-assembled platforms for the delivery of chemotherapeutic drugs

Twenty years ago, the 4 February was declared World Cancer Day with the global challenge of cancer would not be forgotten. Since then, huge progress has been made to understand, prevent, diagnose, and treat cancer. NANBIOSIS as an ICTS (Singular Scientific and Technical infrastructures) for biomedical research plays a very important role in the fight against cancer. Dr. Miriam Royo, who leads NANBIOSIS unit 3 of Synthesis of Peptide, explains one of the projects in which the ICTS is involved in relation with cancer therapy. The improvement of solubility and stability of clinically approved chemotherapeutic drugs still represent a big[...]

26 Feb

A more effective nanomedicine has been developed for the treatment of Fabry rare disease.

28 February: International Rare Disease Day This is one of the major achievements of the European Smart4Fabry project, which is now coming to an end after four years of work.The results have been made possible by nanotechnology and the approach developed could be applied to other drugs in the future.The new drug improves on current treatments and helps reduce costs and improve patients’ quality of life. Barcelona, 26 February 2021.- The advance of nanomedicine opens up new possibilities in the development of drugs, such as the one recently developed for the rare disease Fabry, with improved efficacy compared to existing[...]

11 Feb

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]

U3-Synthesis of Peptides Unit
Read More

U25. NMR: Biomedical Applications I

Ciber bbn

U25. NMR: Biomedical Applications I

  • Scientific Director: Prof. Carles Arús Carles.Arus@uab.es
  • Scientific Coordinator: Ana Paula Candiota AnaPaula.Candiota@uab.cat
  • Entities: Servicio de Resonancia Magnética Nuclear (SeRMN) & Institut de Biotecnología i Biomedicina (IBB) & Universidad Autónoma de Barcelona (UAB)
  • Address: Facultad de Ciencias, Edificio C, 08193, Cerdanyola del Vallés, Barcelona, Spain
  • Phone: +34 935 814 126
  • Web: GABRMN-UAB seRMN-UAB

UAB

Order request

Description

The platform is divided between the Servei de Ressonància Magnètica Nuclear (Nuclear Magnetic Resonance Facility) (SeRMN) and the Institut de Biotecnologia i Biomedicina (IBB) for bioinformatics applications of the UAB. This platform is coordinated by Prof. Carles Arús, PI of the Nuclear Magnetic Resonance Biomedical Applications Group (GABRMN), with a recognized research track record in the use of NMR as a tool for biomedical applications, and more especifically to identify biomarkers of different pathologies. The main objective of the Platform of Biomedical Applications of Nuclear Magnetic Resonance at the Universitat Autònoma de Barcelona (UAB) is the acquisition, processing and/or interpretation of Nuclear Magnetic Resonance data.

The platform is equipped with 10 spectrometers operating at magnetic fields between 5.8 and 14.1 Teslas (T), including a MRI scanner, Bruker BioSpec, equipped with a 7T horizontal magnet for preclinical trials.

The unit also hosts a computational platform at the IBB, with a total storage capacity of 12TB, which is accessible through the UAB network. The computational platform also hosts two multicentre databases (INTERPRET and eTUMOUR), with NMR and clinical data for more than 1000 human brain tumour patients.

The uniqueness in this case lies in access, in the same location, equipment for NMR studies in vivo, ex vivo and in vitro, molecular imaging accessories by using polarization as well as fixed metabolomic patterns. This configuration allows to validate results of molecular imaging in vivo with other in vitro facilities.

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Publications

2016

  • Delgado-Goni T., Ortega-Martorell S., Ciezka M., Olier I., Candiota A.P., Julia-Sape M. et al. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. NMR in Biomedicine. 2016;:-.
  • Cordon-Barris L., Pascual-Guiral S., Yang S., Gimenez-Llort L., Lope-Piedrafita S., Niemeyer C. et al. Mutation of the 3-phosphoinositide-dependent protein kinase 1 (PDK1) substrate-docking site in the developing brain causes microcephaly with abnormal brain morphogenesis independently of akt, leading to impaired cognition and disruptive behaviors. Molecular and Cellular Biology. 2016;36(23):2967-2982.
  • Ferrer-Font L., Alcaraz E., Plana M., Candiota A.P., Itarte E., Arus C.. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma. Pathology and Oncology Research. 2016;:-.
  • Ciezka M., Acosta M., Herranz C., Canals J.M., Pumarola M., Candiota A.P. et al. Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation. Journal of Neuro-Oncology. 2016;:1-10.

News U25

20 Mar

Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior

Doctor Marc Martínez from the Nanomol-Bio group – NANBIOSIS U6 from CIBER-BBN at ICMAB-CSIC, defended his PhD thesis “Nanoparticles to modulate topography and ligand distribution at the nanoscale: impact on cell behavior” on 9 March 2023 at ICMAB. he PhD thesis was supervised by Imma Ratera, Judith Guasch and Nora Ventosa from the Nanomol-Bio group at ICMAB-CSIC. Ana Paula Candiota Silveira, Scientific Coordinator of NANBIOSIS U25 was part of the Committee that evaluated the Thesis tooghether with Jesús Martínez de la Fuente, Instituto de Nanociencia y Materiales de Aragón (INMA-CSIC) (President),  and Anna Lagunas Targarona, Institut de Bioenginyeria de Catalunya (IBEC) (Vocal). As[...]

07 Sep

Philipps-Universität Marburg (Germany) -NANBIOSIS U25 collaboration on the study of tumour microenvironment (TME) changes in Glioblastoma

The scientific coordinator of NANBIOSIS U25 “RNM: Biomedical Application I”, Ana Paula Candiota, was recently awarded with a mobility fellowship from CIBER-BBN for a scientific exchange visit to Philipps-Universität Marburg, in Marburg, Germany. This scientific stage was motivated for a sustained collaboration between the research groups (GABRMN, in charge of U25 and Neurosurgery Lab group in Marburg), regarding the study of tumour microenvironment (TME) changes in Glioblastoma and possible relationship with the noninvasive MRSI-based biomarkers. Both groups have applied together to different funding calls including ERA-NET Transcan and Pathfinder Open, and Marburg group has hosted a predoctoral stage from a[...]

16 Aug

Two NANBIOSIS Units of CIBER-BBN at UAB, one of the 300 best universities in the world, according the Shanghai Ranking

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world. This indicator organizes up to 20,000 university centers worldwide,based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings Two of NANBIOSIS Units created by UAB and CIBER-BBN are part of this university: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Mercedes Marquez, offer an “tailored” service for the design,[...]

05 Jul

Metal-free contrast agents: novel approaches

The joint expertise of CIBER-BBN Nanomol Group – NANBIOSIS U6 from at ICMAB-CSIC (José Vidal and Vega Lloveras) and NANBIOSIS U25 at UAB (Ana Paula Candiota), led to a recently published article in the prestigious journal Biomacromolecules Brain tumours such as Glioblastomas are a challenge in the clinics and proper diagnosis and follow-up are crucial for patient outcome. Contrast agents are usually administered to patients for assessing blood brain barrier integrity and quantitation of enhancing areas are part of the clinical criteria for estimating response/relapse. However, most contrast agents currently used in clinics are based in metal elements such as[...]

10 May

Improving quality of MR spectra from mouse brain. MRSI-detected pattern in glioblastoma patients

Work performed at Unit 25 of Nanbiosis ICTS of “NMR: Biomedical ApplicationsI” is being shown at the Joint annual meeting ISMRM-ESMRMB (May 7-12th) London, with the participation of CIBER-BBN group members Ana Paula Candiota, Silvia Lope-Piedrafita, Miquel Cabañas (abstract 1), Carles Arús, Gulnur Ungan, Margarida Julià-Sapé, Alfredo Vellido and Carles Majós (abstract 2). In the first abstract, entitled “High resolution Multi-voxel spectroscopy using CSI-semi-LASER for mouse brain preclinical studies” we focused into improving quality of MR spectra obtained from mouse brain, a key factor when trying to pursue metabolomic-based biomarkers. The second abstract, entitled “MRSI-detected pattern in glioblastoma patients on[...]

06 Apr

Targeting of the breast cancer stem cells to improve the treatment of triple negative breast cancer

On April 1st PhD candidate Patricia Cámara Sánchez defended her doctoral thesis entitled “Targeting of the breast cancer stem cells to improve the treatment of triple negative breast cancer“, where ICTS-Nanbiosis Unit 20 participated in the in vivo assays. The thesis was supervised by Dr. Ibane Abasolo  (scientific director of Unit 20 from CIBER-BBN and VHIR). Nanbiosis was also present within the jury, with Dr. Ana Paula Candiota (scientific coordinator of Unit 25 from CIBER-BBN and UAB) acting as secretary. Patricia Cámara graduated as biochemist, did the master’s degree in Translational Biomedical Research from VHIR-UAB. Shortly after, started the PhD, which was aimed[...]

19 Jul

Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging

José Vidal Gancedo, researcher from ICMAB-CSIC and CIBER-BBN is leading the project VIRADEN: “In vivo Studies of Radical Dendrimers as Contrast Agents for Magnetic Resonance Imaging“, one of the ICMAB Frontier Interdisciplinary Projects (FIP) 2021. The project aims to evaluate the new contrast agents for MRI based on organic radical dendrimers developed in his group, to substitute the currently used contrast agents based on toxic metals, with the final goal of obtaining useful contrast agents in the early detection of tumors José Vidal has explained NANBIOSIS participation in the project through Biomaterial Processing and Nanostructuring equipments of NANBIOSIS U6 counting wit[...]

03 Jun

Novel nano-encapsulation approach for efficient dopamine delivery in Parkinson’s treatment

UAB Parkinson’s disease (PD) is a common neurodegenerative disorder caused by the death of dopaminergic neurons in a part of the brain (known as substantia nigra pars compacta), which leads to a deficit of dopamine (DA), one of the main neurotransmitters active in the central nervous system. Symptomatic treatment focuses on increasing the concentration of dopamine into the brain.However, dopamine is not directly administered, because it is unable to cross the so called blood-brain barrier, which prevents some of the substances circulating in the blood to penetrate into the nervous system. Thus, DA precursor levodopa (L-DOPA) –an amino-acid which participates[...]

U25-NMR Biomedical Applications I
Read More